The Role of Antisense Therapies Targeting Lipoprotein(a). Issue 1 (July 2021)

• Record Type: Journal Article
• Authors: Plakogiannis, Roda; Sorbera, Maria; Fischetti, Briann; Chen, Mandy
• Is Part Of: Journal of cardiovascular pharmacology. Volume 78:Issue 1(2021)
• Publication Date: 2021-07
• Subjects: lipoprotein(a) -- antisense oligonucleotide -- mipomersen -- volanesorsen -- APO(a)LRx -- cardiovascular residual risk; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000001045
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Abstract: Atherosclerotic cardiovascular disease (ASCVD) continues to be the leading cause of preventable death in the United States. Elevated low-density lipoprotein cholesterol (LDL-C) is well known to result in cardiovascular disease. Mainstay therapy for reducing LDL-C and ASCVD risk is statin therapy. Despite achieving desired LDL-C levels with lipid-lowering therapy, cardiovascular residual risk often persists. Elevated lipoprotein(a) [Lp(a)] levels have been highlighted as an inherent independent predictor of ASCVD, and decreasing Lp(a) levels may result in a significant reduction in the residual risk in high-risk patients. To date, there are no approved medications to lower Lp(a) levels. Nicotinic acid, proprotein convertase subtilisin/kexin 9 inhibitors, and antisense oligonucleotide have demonstrated modest to potent Lp(a) reduction. Spotlight has been placed on antisense oligonucleotides and their role in Lp(a) lowering. APO(a)LRx is in the frontline for selectively decreasing Lp(a) concentrations and ongoing research may prove that this medication may lower Lp(a)-mediated residual risk, translating into cardiovascular benefit.